Wolfe Research initiated Avantor with an Underperform rating and $7 price target, flagging growth and margin challenges that could limit upside versus consensus targets near $8.50.
Alpha Score of 59 reflects moderate overall profile with strong momentum, strong value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Wolfe Research initiated coverage on Avantor (AVTR) with an Underperform rating and a $7 price target, citing persistent growth and margin challenges that could weigh on the stock. The call places the life-sciences supplier among the more bearish on Wall Street, where consensus targets cluster around $8.50, according to data compiled by Bloomberg.
Avantor shares closed near $6.50 Friday, roughly 7% above Wolfe's target, suggesting limited upside even if the company meets current expectations. The research firm flagged that the company has struggled to sustain revenue momentum after a post-pandemic demand pull-forward, and that operating margins have compressed as input costs rose faster than pricing.
The Underperform rating comes weeks after Evercore ISI trimmed its own price target to $8.50 while maintaining a Neutral stance, citing similar headwinds from inventory destocking and currency effects. Evercore's analysts noted that Avantor's exposure to bioprocessing–a segment that boomed during COVID–has become a drag as drugmakers work through excess supplies.
Avantor sells lab supplies, chemicals, and equipment to pharmaceutical and biotech customers. The company's recent quarterly results showed a 4% revenue decline year-over-year, with adjusted EBITDA margins slipping 150 basis points. Management has pointed to a recovery in the second half of 2025, though Wolfe Research appears skeptical that the turnaround will materialise quickly enough.
Wolfe's price target of $7 implies a forward EV/EBITDA multiple of roughly 11 times, a discount to Avantor's historical average of 14 times. The discount reflects the risk that margin recovery takes longer than the market anticipates, particularly if bioprocessing demand remains soft into 2026.
Avantor remains unscored by AlphaScala's proprietary system, which currently labels the stock as Unscored in the Healthcare sector. The stock page on the platform tracks insider transactions and institutional ownership, though no trading signal is active.
Wolfe Research's initiation adds to a mixed analyst consensus. Of the 18 analysts covering Avantor, nine rate it a Buy, six a Hold, and three an Underperform or Sell, according to Bloomberg. The average 12-month price target stands at $8.70, implying roughly 34% upside from current levels–a gap that Wolfe argues may be too optimistic.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.